Thought Leadership

Latest Report


Evaluate Vantage Report: US Approvals Under the Spotlight

On April 27-29, a three-day US advisory committee meeting convenes. Their objective is to scrutinise the accelerated approvals of certain anti-PD-(L)1 drugs whose confirmatory trials have failed. Will the US FDA's standards change after years of apparent leniency? 'US Approvals Under the Spotlight', the latest report from Evaluate Vantage,…

Report library


Evaluate Vantage 2021 Preview

Biopharma’s role in trying to bring the COVID-19 pandemic to an end has made household names of companies large and small, and cutting-edge technologies like mRNA…


Evaluate Vantage COVID-19 Report

Biopharma and Medtech are leading the fight against COVID-19, but are not immune from the significant economic impact of the pandemic. The COVID-19 pandemic is having a…